ARTICLE | Clinical News
OREX-003: Phase IIa started
October 6, 2008 7:00 AM UTC
Orexigen began a double-blind, placebo-controlled, U.S. Phase IIa trial (OZ-101) to evaluate 10 to 20 mg of daily olanzapine plus 360 mg zonisamide SR or placebo for 10 weeks in 75 patients with schiz...